From Liston Street Pulse:
Drug maker AstraZeneca Plc (AZN) announced on Monday that its biological drugs division, Medlmmune will acquire Amplimmune in a deal valued at $500 million. Amplimmune focuses on drugs that try to harness the human immune system to battle cancer. The deal comes after a spate of acquisitions by AstraZeneca. The Company has been expanding its […]
The post AstraZeneca To Acquire Amplimmune appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015